hims fda warning letter compounded semaglutide 2025 Novo Nordisk calls out dangers of GLP-1s in new ad Hims & Hers' Super Bowl

"I'd like to congratulate both parties on this deal following our recent action." The FDA last month said it would take decisive steps against companies mass-marketing illegal copycat drugs, including Hims, spurring the company to reverse course on selling a copy of Novo's pill

famata , and itaconate and oxalate inhibiting isocitrate lyase for fatty acid use in Aphis gossipii are employed for selection of fungal riboflavin overproducing strains (Park et al., 2007

In April 2026, the FDA approved Eli Lillys Foundayo (orforglipron), a once-daily oral GLP-1 agonist medicine for weight loss and maintenance in adults with obesity or overweight

If you experience migraine symptoms on 15 or more days each month, you have chronic migraine

doi: 10.7150/ijbs.78654